Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

<p>Multiplex immunohistochemical staining protocols.</p>

Збережено в:

Бібліографічні деталі
Автор:	Hansol Lee (15054787) (author)
Інші автори:	Angela L. Ferguson (15050051) (author), Camelia Quek (15049218) (author), Ismael A. Vergara (15054784) (author), Ines Pires daSilva (15056800) (author), Ruth Allen (15056803) (author), Tuba Nur Gide (15056806) (author), Jordan W. Conway (15056809) (author), Lambros T. Koufariotis (15056812) (author), Nicholas K. Hayward (14956488) (author), Nicola Waddell (12694196) (author), Matteo S. Carlino (15056815) (author), Alexander M. Menzies (11420816) (author), Robyn P.M. Saw (15056818) (author), Elena Shklovskaya (15056821) (author), Helen Rizos (15008946) (author), Serigne Lo (15056824) (author), Richard A. Scolyer (10778711) (author), Georgina V. Long (11420813) (author), Umaimainthan Palendira (15050084) (author), James S. Wilmott (15008931) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers Prognostic biomarkers Immunology Immune responses to cancer Innate immunity Tumor-associated macrophages Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Combination immunotherapy Skin Cancers Melanoma
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
за авторством: Hansol Lee (15054787)
Опубліковано: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
за авторством: Renumathy Dhanasekaran (14962092)
Опубліковано: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
за авторством: Hiroshi Kagamu (14961732)
Опубліковано: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
за авторством: Huaibin Ge (15047462)
Опубліковано: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
за авторством: Andrew O. Yam (15293045)
Опубліковано: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
за авторством: Andrew O. Yam (15293045)
Опубліковано: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
за авторством: Andrew O. Yam (15293045)
Опубліковано: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
за авторством: Andrew O. Yam (15293045)
Опубліковано: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
за авторством: Andrew O. Yam (15293045)
Опубліковано: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
за авторством: Daniel S. Green (15047598)
Опубліковано: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
за авторством: Carlotta Antoniotti (15352506)
Опубліковано: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
за авторством: Caroline Robert (15032672)
Опубліковано: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
за авторством: Arianna Draghi (15126339)
Опубліковано: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
за авторством: Arianna Draghi (15126339)
Опубліковано: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
за авторством: Arianna Draghi (15126339)
Опубліковано: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
за авторством: Jonathan M.J. Derry (16648337)
Опубліковано: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
за авторством: Sahar Mafi (16721657)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_rirqafet4b8r52v8k2s7rpicja